List of Reyvow drug patents

Reyvow is owned by Eli Lilly And Co.

Reyvow contains Lasmiditan Succinate.

Reyvow has a total of 3 drug patents out of which 0 drug patents have expired.

Reyvow was authorised for market use on 31 January, 2020.

Reyvow is available in tablet;oral dosage forms.

Reyvow can be used as acute treatment of migraine.

Drug patent challenges can be filed against Reyvow from February, 2024.

The generics of Reyvow are possible to be released after 05 December, 2037.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7423050 ELI LILLY AND CO Pyridinoylpiperidines as 5-HT1F agonists
Apr, 2025

(2 years from now)

US11053214 ELI LILLY AND CO Compositions and methods related to pyridinoylpiperidine 5-HT1F agonists
Dec, 2037

(14 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8748459 ELI LILLY AND CO Pyridinoylpiperidines as 5-HT1F agonists
Mar, 2023

(a month from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Jan 31, 2025

Drugs and Companies using LASMIDITAN SUCCINATE ingredient

NCE-1 date: February, 2024

Market Authorisation Date: 31 January, 2020

Treatment: Acute treatment of migraine

Dosage: TABLET;ORAL

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic